|
1
|
Muto T, Kotake K and Koyama Y: Colorectal
cancer statistics in Japan: data from JSCCR registration,
1974–1993. Int J Clin Oncol. 6:171–176. 2001.PubMed/NCBI
|
|
2
|
Koyama Y and Kotake K: Overview of
colorectal cancer in Japan: report from the Registry of the
Japanese Society for Cancer of the Colon and Rectum. Dis Colon
Rectum. 40:2–9. 1997. View Article : Google Scholar
|
|
3
|
Fidler IJ and Ellis LM: The implications
of angiogenesis for the biology and therapy of cancer metastasis.
Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
LeCouter J, Kowalski J, Foster J, Hass P,
Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller
GA, et al: Identification of an angiogenic mitogen selective for
endocrine gland endothelium. Nature. 412:877–884. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soga T, Matsumoto S, Oda T, Saito T,
Hijama H, Takasaki J, Kamohara M, Ohishi T, Matsushime H and
Furuichi K: Molecular cloning and characterization of prokineticin
receptors. Biochim Biophys Acta. 1579:173–179. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin DC, Bullock CM, Eheler FJ, Chen JL,
Tian H and Zhou QY: Identification and molecular characterization
of two closely related G protein-coupled receptors activated by
prokineticins/endocrine gland vascular endothelial growth factor. J
Biol Chem. 277:19276–19280. 2002. View Article : Google Scholar
|
|
7
|
Masuda Y, Takatsu Y, Terao Y, Kumano S,
Ishibashi Y, Suenaga M, Abe M, Fukusumi S, Watanabe T, Shintani Y,
et al: Isolation and identification of EG-VEGF/prokineticins as
cognate ligands for two orphan G-protein-coupled receptors. Biochem
Biophys Res Commun. 293:396–402. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goi T, Yamaguchi A, Nakagawara G, Urano T,
Shiku H and Furukawa K: Reduced expression of deleted colorectal
carcinoma (DCC) protein in established colon cancers. Br J Cancer.
77:466–471. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamaguchi A, Urano T, Goi T, Saito M,
Takeuchi K, Hirose K, Nakagawara G, Shiku H and Furukawa K:
Expression of a CD44 variant containing exons 8 to 10 is a useful
independent factor for the prediction of prognosis in colorectal
cancer patients. J Clin Oncol. 14:1122–1127. 1996.PubMed/NCBI
|
|
10
|
Fujishima Y, Goi T, Kimura Y, Hirono Y,
Katayama K and Yamaguchi A: MUC2 protein expression status is
useful in assessing the effects of hyperthermic intraperitoneal
chemotherapy for peritoneal dissemination of colon cancer. Int J
Oncol. 40:960–964. 2012.
|
|
11
|
Sawai K, Goi T, Hirono Y, Katayama K and
Yamaguchi A: Survivin-3B gene decreases the invasion-inhibitory
effect of colon cancer cells with 5-fluorouracil. Oncol Res.
18:541–547. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goi T, Yamaguchi A, Takeuchi K, Nakagawa
G, Yamashiro S, Furukawa K, Urano T and Shiku H: CD44 with variant
exons 8-10 in colorectal tumors: expression analysis by a variant
exon 9-specific monoclonal antibody. Int J Oncol. 8:657–662.
1996.PubMed/NCBI
|
|
13
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sakurai T and Kudo M: Signaling pathways
governing tumor angiogenesis. Oncology. 81:24–29. 2011. View Article : Google Scholar
|
|
15
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar
|
|
16
|
Andrae J, Gallini R and Betsholtz C: Role
of platelet-derived growth factors in physiology and medicine.
Genes Dev. 22:1276–1312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giantonio BJ, Catalano PJ, Meropol NJ,
O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB III:
Bevacizumab in combination with oxaliplatin, fluorouracil, and
leucovorin (FOLFOX4) for previously treated metastatic colorectal
cancer: results from the Eastern Cooperative Oncology Group Study
E3200. J Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar
|
|
19
|
Jonker DJ, O’Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Van Cutsem E, Nowacki M, Lang I, Cascinu
S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J and
Kohne C: Randomized phase III study of irinotecan and 5-FU/LV with
or without cetuximab in the first line treatment of patients with
metastatic colorectal cancer. J Clin Oncol. 25:40002007.
|
|
22
|
Van Cutsem E, Peeters M, Siena S, Humblet
Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J,
Richardson G, et al: Open-label phase III trial of panitumumab plus
best supportive care compared with best supportive care alone in
patients with chemotherapy-refractory metastatic colorectal cancer.
J Clin Oncol. 25:1658–1664. 2007.PubMed/NCBI
|
|
23
|
Nagano H, Goi T, Koneri K, Hirono Y,
Katayama K and Yamaguchi A: Endocrine gland-derived vascular
endothelial growth factor (EG-VEGF) expression in colorectal
cancer. J Surg Oncol. 96:605–610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goi T, Fujioka M, Satoh Y, Tabata S,
Koneri K, Nagano H, Hirono Y, Katayama K, Hirose K and Yamaguchi A:
Angiogenesis and tumor proliferation/metastasis of human colorectal
cancer cell line SW620 transfected with endocrine
gland-derived-vascular endothelial growth factor, as a new
angiogenic factor. Cancer Res. 64:1906–1910. 2004. View Article : Google Scholar
|
|
25
|
Ngan ES, Sit FY, Lee K, Miao X, Yuan Z,
Wang W, Nicholls JM, Wong KK, Garcia-Barcelo M, Lui VC and Tam PK:
Implications of endocrine gland-derived vascular endothelial growth
factor/prokineticin-1 signaling in human neuroblastoma progression.
Clin Cancer Res. 13:868–875. 2007. View Article : Google Scholar
|
|
26
|
Pasquali D, Rossi V, Staibano S, De Rosa
G, Chieffi P, Prezioso D, Mirone V, Mascolo M, Tramontano D,
Bellastella A and Sinisi AA: The endocrine-gland-derived vascular
endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and
receptor expression in human prostate: up-regulation of
EG-VEGF/prokineticin 1 with malignancy. Endocrinology.
147:4245–4251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Morales A, Vilchis F, Chávez B, Chan C,
Robles-Díaz G and Díaz-Sánchez V: Expression and localization of
endocrine gland-derived vascular endothelial growth factor
(EG-VEGF) in human pancreas and pancreatic adenocarcinoma. J
Steroid Biochem Mol Biol. 107:37–41. 2007. View Article : Google Scholar
|
|
28
|
Jiang X, Abiatari I, Kong B, Erkan M, De
Oliveira T, Giese NA, Michalski CW, Friess H and Kleeff J:
Pancreatic islet and stellate cells are the main sources of
endocrine gland-derived vascular endothelial growth
factor/prokineticin-1 in pancreatic cancer. Pancreatology.
9:165–172. 2009.
|
|
29
|
Chakraborti S, Mandal M, Das S, Mandal A
and Chakraborti T: Regulation of matrix metalloproteinases: an
overview. Mol Cell Biochem. 253:269–285. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rydlova M, Holubec L Jr, Ludvikova M Jr,
Kalfert D, Franekova J, Povysil C and Ludvikova M: Biological
activity and clinical implications of the matrix
metalloproteinases. Anticancer Res. 28:1389–1397. 2008.PubMed/NCBI
|
|
31
|
Zucker S and Vacirca J: Role of matrix
metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis
Rev. 23:101–117. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tomita T and Iwata K: Matrix
metaIloproteinases and tissue inhibitors of metalloproteinases in
colonic adenomas-adeno-carcinomas. Dis Colon Rectum. 39:1255–1264.
1996. View Article : Google Scholar : PubMed/NCBI
|
